Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I ABI-007 (nab-paclitaxel) plus gemcitabine as adjuvant therapy after pancreatic cancer resection
jRCT2080223124Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Mar 2016
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nab-paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Taiho Pharmaceutical Co., Ltd. Started Mar 2016; status: completed.
02
Drugs
nab-paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2080223124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223124.